Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
|
| gptkbp:activeIngredient |
gptkb:fluoxetine
|
| gptkbp:approvalYear |
2000
|
| gptkbp:ATCCode |
gptkb:N06AB03
|
| gptkbp:chemicalFormula |
C17H18F3NO
|
| gptkbp:contains |
fluoxetine hydrochloride
|
| gptkbp:contraindication |
MAOI use
hypersensitivity to fluoxetine |
| gptkbp:drugClass |
selective serotonin reuptake inhibitor
|
| gptkbp:form |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sarafem
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketedAs |
treatment for PMDD
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:sideEffect |
nausea
headache insomnia sexual dysfunction |
| gptkbp:usedFor |
gptkb:depression
premenstrual dysphoric disorder |
| gptkbp:bfsParent |
gptkb:Prozac
gptkb:fluoxetine |
| gptkbp:bfsLayer |
6
|